Ocular Therapeutix
OCUL
72 hedge funds and large institutions have $144M invested in Ocular Therapeutix in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 14 closing their positions.
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
1% less funds holding
Funds holding: 73 → 72 (-1)
10% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $2.02M
10.38% less ownership
Funds ownership: 63.79% → 53.41% (-10%)
16% less capital invested
Capital invested by funds: $170M → $144M (-$26.6M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$3.26M |
| 2 |
BlackRock
New York
|
+$865K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$571K |
| 4 |
CI
Cowen Inc
New York
|
+$476K |
| 5 |
State Street
Boston,
Massachusetts
|
+$395K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$11.9M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.1M |
| 3 |
CCI
Columbus Circle Investors
|
-$4.94M |
| 4 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$3.56M |
| 5 |
Morgan Stanley
New York
|
-$1.99M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Renaissance Technologies
New York
| – | -$825K | -88,900 | Closed |
|
77
SG Americas Securities
New York
| – | -$455K | -49,024 | Closed |
|
|
VKH
78
Virtu KCG Holdings
New York
| – | -$402K | -43,284 | Closed |
|
|
DTL
79
Dynamic Technology Lab
Singapore
| – | -$195K | -21,062 | Closed |
|
|
EMG
80
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$113K | -12,200 | Closed |
|
|
HCM
81
Highbridge Capital Management
New York
| – | -$107K | -11,544 | Closed |
|
|
V
82
Veritable
Wilmington,
Delaware
| – | -$93K | -10,000 | Closed |
|
|
NIT
83
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$86K | -9,300 | Closed |
|
84
Group One Trading
Chicago,
Illinois
| – | -$49.9K | -5,160 | Closed |
|
|
CAG
85
Crestwood Advisors Group
Boston,
Massachusetts
| – | -$26K | -2,900 | Closed |
|
|
MAM
86
Meeder Asset Management
Dublin,
Ohio
| – | -$7K | -756 | Closed |
|
OCUL Hedge Fund Activity: Q2 2017 in Review
72 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2017, worth a combined $144M — down 16% from $170M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of OCUL and 13 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 22 added.
The largest buyer was JP Morgan Private Wealth Advisors, opening a new position worth an estimated $3.26M. The largest seller was Jennison Associates, cutting an estimated $11.9M.
- 72 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2017, down from 73 in Q1 2017.
- Funds reported $144M of Ocular Therapeutix stock for Q2 2017, down 16% quarter-over-quarter.
- 13 funds opened new Ocular Therapeutix positions in Q2 2017 and 14 closed out, a net change of -1 holder.
- The largest Ocular Therapeutix buyer in Q2 2017 was JP Morgan Private Wealth Advisors, an estimated $3.26M added.
- The largest Ocular Therapeutix seller in Q2 2017 was Jennison Associates, an estimated $11.9M sold.
Based on aggregated 13F filings for Q2 2017.